Researchers from the University of Washington have developed an investigational vaccine that can safely elicit an immune response against the HER2 protein, a key marker in breast cancer.
https://www.pharmalive.com/wp-content/uploads/2022/09/Cancervaccines-woman.jpeg350625BioSpacehttps://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.pngBioSpace2022-11-08 10:55:572022-11-08 10:55:5780% of patients in Phase I breast cancer vaccine trial alive after 10 years
